Real-world data ‘back long-term anakinra safety’

Paediatric rheumatologists have drawn on a European registry to evaluate adverse events

Clinicians can be confident about the long-term safety profile of the interleukin-1 receptor antagonist anakinra for systemic juvenile idiopathic arthritis, researchers say.

Although adverse events are common, the overall incidence gradually decreases over time, according to their study based on the observational Pharmachild registry of patients with systemic juvenile idiopathic arthritis (sJIA).